In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
22 authors.
Vincent AllainDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-1068-7892 Allison G RothrockDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.
Pierre-Louis BernardDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-6567-619X William A NybergDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-9982-1305 Alexis TalbotDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-6734-413X Joseph J MuldoonDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-3784-3565 Jing-Yi ChungDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-5801-2416 Angela ToDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-4622-0039 Christopher R ChangDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-3124-8773 Gabriella R KimmerlyDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-2920-2218 Chang LiuDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0009-0003-1294-9686 Tasha TsaoBiomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-1183-8912 Yasaman MortazaviGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, United States.
Jin SeoGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, United States.
Zhongmei LiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, United States.
Avishai ShemeshDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-6934-7155 Alexander MarsonDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-2734-5776 Lewis L LanierDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0003-1308-3952 Oscar A AguilarDepartment of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0002-7990-8745 Justin EyquemDepartment of Medicine, University of California, San Francisco, San Francisco, CA, United States.ORCID 0000-0001-8262-1190 Funding
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8MMedical Scientist Training Program (T32 NRSA Training Grant)T32GM141323 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Aimee Kao · 2021 to 2026
$10.5MExpanding the scope of protein degradation and stability using chemoproteomic platformsK00CA245718 · NCI · J. DAVID GLADSTONE INSTITUTES · PI WARD, CARL · 2021 to 2024
$371kNCI NIH HHS K00 CA245718NIDDK NIH HHS P30 DK063720NIGMS NIH HHS T32 GM141323
6 · The paper itselfAbstract
Natural killer (NK) cells are emerging as a promising platform for engineered adoptive cell therapies. However, gene editing in NK cells remains challenging, and more effective strategies are needed. Here, we established a robust, feeder-free, and modular workflow for genome engineering in primary human NK cells, combining CRISPR/Cas9 with AAV6-mediated transgene delivery. Efficient site-specific transgene integration was achieved at various loci and can be coupled with concurrent disruption of the target locus in a single editing step. Furthermore, transgene expression was tunable according to the integration site and promoter. We applied this strategy to target a chimeric antigen receptor (CAR) transgene to a panel of inhibitory NK receptor loci, establishing a synergistic approach to enhance anti-tumor activity and facilitate the reliable comparison of CAR variants without expression bias. We identified
Identifiers
PMID41279666
PMCPMC12632371
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390